Unibest
← Back to patent-cliff list

CAS 1132940-88-5

N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-yl)methanesulfonamide

Codes: DASA-007

Application context (from source-drug indications)

Chronic hepatitis CDasabuvir Sodium HydrateHepatitis CDasabuvir Sodium HydrateDecompensated cirrhosisDasabuvir Sodium HydrateRenal impairmentDasabuvir Sodium HydrateFibrosisDasabuvir Sodium HydrateEnd-stage renal diseaseDasabuvir Sodium Hydrate

Source drugs (routes using this intermediate)

DrugTierExpiry
Dasabuvir Sodium HydrateTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Dasabuvir Sodium HydrateOriginator routesteps: 13total yield: 53 mg
Dasabuvir Sodium HydrateOptimised routesteps: 4total yield: 20.74 g

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.